Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor

Antiviral Therapy

Volumn 17, Issue 5, 2012, Pages 921-926

  Plaza, Zulema ^a   Soriano, Vincent ^a   Vispo, Eugenia ^a   Gonzalez, Maria Del Mar ^a   Barreiro, Pablo ^a   Seclén, Eduardo ^a   Poveda, Eva ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; NONSTRUCTURAL PROTEIN 5A;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CODON; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NS5A GENE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SPAIN; VIRUS GENE; VIRUS MUTANT;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84858415895     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2091     Document Type: Article

References (11)

1. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65:202-212.
2. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355:2444-2451.
3. Soriano V, Vispo E, Poveda E, et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011; 66:1673-1686.
4. De Meyer S, Dierynck I, Ghys A, et al. Similar incidence of virological failure and emergence of resistance with or without a lead-in: results of a telaprevir Phase 3 study in patients who did not achieve SVR with prior Peg-IFN/RBV treatment. Antivir Ther 2011; 16 Suppl 1:A25.
5. Lenz O, Vijgen L, Moreno C, et al. Virological response and characterization of HCV genotypes 2 to 6 under TMC-435 monotherapy (study TMC-435-C202). Antivir Ther 2011; 16 Suppl 1:A24.
6. Gao M, Nettles R, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
7. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem 2004; 279:48576-48587.
8. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54:3641-3650.
9. Lemm JA, O'Boyle D, Liu M, et al. Identification of hepatitis C virus NS5A inhibitors. J Virol 2010; 84:482-491.
10. Zeuzem S, Asselah T, Angus P, et al. Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI-201335, the HCV polymerase inhibitor BI-207127, and ribavirin, in patients with chronic hepatitis C: the SOUND-C1 trial. 61st Annual Meeting of the American Associations for the Study of Liver Diseases. 29 October-2 November 2010, Boston, MA, USA. Abstract LB-7.
11. Schinazi R, Zhang H-W, Zhou L, et al. Synthesis and characterization of picomolar inhibitors of HCV NS5A in hepatocytes. Antivir Ther 2011; 16 Suppl 1:A22.